Stefania Sciallero

Stefania Sciallero

Auto-generated profile, based on publicly available information

Stefania Sciallero

Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2011 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
NSNereo Segnan
Nereo Segnan
PAPaola Armaroli
Paola Armaroli
LBLuigina Bonelli
Luigina Bonelli
MRMauro Risio
Mauro Risio
SSStefania Sciallero
Stefania Sciallero
TGthe SCORE Working Group
the SCORE Working Group
A single flexible sigmoidoscopy at around the age of 60 years has been proposed as an effective strategy for colorectal cancer (CRC) screening. We conducted a randomized controlled trial to evaluate the effect of flexible sigmoidoscopy screening on CRC incidence and mortality. A questionnaire to assess the eligibility and interest in screening was mailed to 236 568 men and women, aged 55–64 years, who were randomly selected from six trial centers in Italy. Of the 56 532 respondents, interested and eligible subjects were randomly assigned to the intervention group (invitation for flexible sigmoidoscopy; n = 17 148) or the control group (no further contact; n = 17 144), between June 14, 1995, and May 10, 1999. Flexible sigmoidoscopy was performed on 9911 subjects. Intention-to-treat and per-protocol analyses were performed to compare the CRC incidence and mortality rates in the intervention and control groups. Per-protocol analysis was adjusted for noncompliance. A total of 34 272 subjects (17 136 in each group) were included in the follow-up analysis. The median follow-up period was 10.5 years for incidence and 11.4 years for mortality; 251 subjects were diagnosed with CRC in the intervention group and 306 in the control group. Overall incidence rates in the intervention and control groups were 144.11 and 176.43, respectively, per 100 000 person-years. CRC-related death was noted in 65 subjects in the intervention group and 83 subjects in the control group. Mortality rates in the intervention and control groups were 34.66 and 44.45, respectively, per 100 000 person-years. In the intention-to-treat analysis, the rate of CRC incidence was statistically significantly reduced in the intervention group by 18% (rate ratio [RR] = 0.82, 95% confidence interval [CI] = 0.69 to 0.96), and the mortality rate was non-statistically significantly reduced by 22% (RR = 0.78; 95% CI = 0.56 to 1.08) compared with the control group. In the per-protocol analysis, both CRC incidence and mortality rates were statistically significantly reduced among the screened subjects; CRC incidence was reduced by 31% (RR = 0.69; 95% CI = 0.56 to 0.86) and mortality was reduced by 38% (RR = 0.62; 95% CI = 0.40 to 0.96) compared with the control group. A single flexible sigmoidoscopy screening between ages 55 and 64 years was associated with a substantial reduction of CRC incidence and mortality.

24 February 2012 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
Paola GhiorzoPaola Ghiorzo
Paola Ghiorzo
GFGiuseppe Fornarini
Giuseppe Fornarini
SSStefania Sciallero
Stefania Sciallero
LBLinda Battistuzzi
Linda Battistuzzi
FBFiorenza Belli
Fiorenza Belli
TGthe Genoa Pancreatic Cancer Study Group
the Genoa Pancreatic Cancer Study Group
Background: Most familial pancreatic cancer (FPC) remains unexplained. The identification of individuals with a high genetic risk of developing pancreatic adenocarcinoma (PC) is important to elucidate its biological basis and is critical to better define emerging strategies for the detection of early pancreatic neoplasms. Patients and methods: A series of 225 consecutively enrolled patients with PC were tested for CDKN2A mutations. After personal and family cancer histories of all the patients had been reviewed, a subset of the patients were classified as FPC and were also tested for mutations in PALLD, PALB2, BRCA1 and BRCA2 as FPC candidate genes. Results: The CDKN2A mutation rate in the 225 PC cases was 5.7%. The CDKN2A founder mutations, p.E27X and p.G101W, were predominant, but the mutation spectrum also included p.L65P, p.G67R and two novel, potentially pathogenic variants, promoter variant c.-201ACTC>CTTT and p.R144C. None of the patients with FPC harboured germline mutations in PALLD, PALB2 or BRCA2. One family was positive for the BRCA1 UV variant p.P727L. Strikingly, five of 16 patients with FPC (31%) carried CDKN2A mutations. Conclusion: These findings suggest that a sizeable subset of Italian FPC families may carry CDKN2A mutations. This result may be of value for identifying the best candidates for future PC screening trials in Italy.

17 April 2013 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
DFDaniela Fenoglio
Daniela Fenoglio
PTPaolo Traverso
Paolo Traverso
APAlessia Parodi
Alessia Parodi
LTLaura Tomasello
Laura Tomasello
SNSimone Negrini
Simone Negrini
GFGilberto Filaci
Gilberto Filaci

1 April 1991 in Cancer
Verified
Journal Article
Open access
PDF file
WGWalter Giaretti
Walter Giaretti
MDMarco Danova
Marco Danova
EGElio Geido
Elio Geido
GMGiuliano Mazzini
Giuliano Mazzini
SSStefania Sciallero
Stefania Sciallero
EDEmanuele S. G. D'AMore
Emanuele S. G. D'AMore
The authors investigated the relationship between flow cytometric DNA index (DI, defined as the ratio of the DNA content of malignant cells to that of normal cells) and other prognostic factors (grade and stage, anatomical site, age and sex) with the survival of 115 patients with colorectal cancer. Multiple biopsy specimens from 62 patients were taken during colonoscopy before surgery. Additional samples from 53 patients were obtained from paraffin‐embedded material. All patients were treated with surgery only. Fresh–frozen material gave higher incidence of DNA aneuploidy than paraffin‐embedded material (79% versus 41%). The patients with DNA diploid tumors (DI = 1) had a better overall survival than those with DNA aneuploid tumors (DI > 1). Among DNA aneuploid tumors, those with DI > 1.2 (excluding DI = 2) were worse than those with DI > 1.2 (excluding DI = 1) and DI = 2. Cox's regression analysis showed that pathologic stage was more important for prognosis than DNA index, whereas age, sex, histologic grade, and anatomic site were removed from the analysis as not relevant for prognosis. Relative risks of death (RR), in reference to patients with DI = 1 and Stages A + B (RR = 1), were RR = 1.8 for patients with carcinomas with Stage C, RR = 2.7 for patients with carcinomas with DNA near‐diploid and DNA tetraploid tumors, RR = 3.5 for those with DI > 1.2 (excluding DI = 2), and RR = 8.0 for those with Stage D. These data indicate that flow cytometrically evaluated DI values have a relevant independent power for predicting the clinical outcome of colorectal cancer patients.

14 April 2021 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
MAManuela Albertelli
Manuela Albertelli
ADAndrea Dotto
Andrea Dotto
FNFederica Nista
Federica Nista
AVAlessandro Veresani
Alessandro Veresani
LPLuca Patti
Luca Patti
DFDiego Ferone
Diego Ferone
Immunotherapy, so promising in many neoplasms, still does not have a precise role in the treatment of neuroendocrine neoplasms (NENs). In this article, we provide an overview on the current knowledge about immunotherapy with immune checkpoint inhibitors (ICIs) applied to NENs, evaluating future perspectives in this setting of tumors.Evidence so far available for ICIs in gastroenteropancreatic (GEP)-NENs is definitively not as robust as for other tumors such as Small Cell Lung Cancer or Merkel Cell Carcinoma. In fact, with regard to the well-differentiated forms of NENs (NETs), the results obtained nowadays have been disappointing. However, the near future, might reserve interesting results for ICIs in GEP-NEN from a total of nine different ICI drugs, used throughout 19 randomised controlled trials. Such numbers highlight the growing attention gathering around NENs and ICIs, in response to the need of stronger evidences supporting such therapy.For the future, the most important aspect will be to study strategies that can make NETs more susceptible to response to ICI and, thus, enhance the effectiveness of these treatments. Therefore, the combination of conventional therapy, target therapy and immunotherapy deserve attention and warrant to be explored. A sequential chemotherapy, possibly inducing an increase in tumor mutational burden and tested before immunotherapy, could be a hypothesis deserving more consideration. A radiation treatment that increases tumor-infiltrating lymphocytes, could be another approach to explore before ICIs in NENs. Equally essential will be the identification of biomarkers useful for selecting patients potentially responsive to this type of treatment.

9 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FCFabio Catalano
Fabio Catalano
RBRoberto OF Borea
Roberto OF Borea
SPSilvia Puglisi
Silvia Puglisi
ABAndrea Boutros
Andrea Boutros
AGAnnalice Gandini
Annalice Gandini
Alberto PucciniAlberto Puccini
Alberto Puccini
Major advances have been made in CRC treatment in recent years, especially in molecularly driven therapies and immunotherapy. Despite this, a large number of advanced colorectal cancer patients do not benefit from these treatments and their prognosis remains poor. The landscape of DNA damage response (DDR) alterations is emerging as a novel target for treatment in different cancer types. PARP inhibitors have been approved for the treatment of ovarian, breast, pancreatic, and prostate cancers carrying deleterious BRCA1/2 pathogenic variants or homologous recombination repair (HRR) deficiency (HRD). Recent research reported on the emerging role of HRD in CRC and showed that alterations in these genes, either germline or somatic, are carried by up to 15–20% of CRCs. However, the role of HRD is still widely unknown, and few data about their clinical impact are available, especially in CRC patients. In this review, we report preclinical and clinical data currently available on DDR inhibitors in CRC. We also emphasize the predictive role of DDR mutations in response to platinum-based chemotherapy and the potential clinical role of DDR inhibitors. More preclinical and clinical trials are required to better understand the impact of DDR alterations in CRC patients and the therapeutic opportunities with novel DDR inhibitors.